As reported in Biospace, the life sciences company Revive Therapeutics Ltd. has announced their intention to join a Clinical Trial Agreement (CTA) with the Board of Regents of the University of Wisconsin System (UWS) to begin a Phase 1 study of the use of psilocybin to treat adults who are recovering from methamphetamine use disorder. The drug could potentially be the first pharmaceutical option to treat the disorder that results from the use of the illicit drug.

Methamphetamine use disorder is the name for a set of symptoms resulting from habitual use of methamphetamine. This can include impairments and issues such as anxiety, paranoia, hallucination, impaired motor skills, damaged memory, withdrawal, and failure to meet other responsibilities with work and family life. There is no pharmaceutical treatment currently available, rather the disorder is treated with different therapies and management plans.

The study, “Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder” could find the first pharmaceutical treatment ever for these patients. The CEO of Revive, the manufacturing firm, Michael Frank, has stated how excited he is to be working with the University of Wisconsin. Being able to help those with addiction and substance abuse problems is very important to both organizations, and they want to help through creating a pipeline of therapies derived from psychedelics. They will be focusing on psilocybin and its unique dosage forms.